.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Healthtrust
Teva
Chinese Patent Office
Farmers Insurance
Merck
Cipla
US Department of Justice
UBS

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,858,662

« Back to Dashboard

Which drugs does patent 7,858,662 protect, and when does it expire?


Patent 7,858,662 protects VEREGEN and is included in one NDA.

This patent has twenty-nine patent family members in twenty countries.

Summary for Patent: 7,858,662

Title:Medicament for the treatment of viral skin and tumour diseases
Abstract: The invention relates to a medicament containing a compound of general formula (1), where R.sub.1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkynyl group, preferably a C.sub.11-C.sub.15 alkyl, alkylene or alkynyl group, particularly a C.sub.11-C.sub.13 alkyl, alkylene or alkynyl group, most preferably a C.sub.13 alkyl group, R2=independently, a straight or branched C.sub.1-C.sub.8 alkyl, alkylene or alkynyl group, preferably a C.sub.1-C.sub.6 alkyl, alkylene or alkynyl group, in particular a C.sub.2-C.sub.4 alkyl, alkylene or alkynyl group, most preferably a C.sub.3 alkyl group, a --[CH.sub.2--(CH.sub.2).sub.m--O].sub.nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a --CH.sub.2--[CH--(OH)].sub.p[CH.sub.2--(R.sub.3)]-- group, where R.sub.3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. ##STR00001##
Inventor(s): Chang; Yunik (Sonoma, CA), Lathrop; Robert (Fort Collins, CO), Bohm; Erwin (Ladenburg, DE), Gander-Meisterernst; Irene (Stockdorf, DE), Greger; Regina (Iffeldorf, DE), Holldack; Johanna (Ebeltoft, DK), Moebius; Ulrich (Gauting-Unterbrunn, DE)
Assignee: MediGene AG (Planegg, DE)
Application Number:10/495,889
Patent Claim Types:
see list of patent claims
Compound; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medigene Ag
VEREGEN
sinecatechins
OINTMENT;TOPICAL021902-001Oct 31, 2006RXYesYes► Subscribe► SubscribeY TREATMENT OF GENITAL WARTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,858,662

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 56 794Nov 19, 2001
PCT Information
PCT FiledNovember 18, 2002PCT Application Number:PCT/EP02/12919
PCT Publication Date:May 30, 2003PCT Publication Number: WO03/043628

Non-Orange Book Patents for Patent: 7,858,662

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,770,406Medicament for the treatment of viral skin and tumour diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,858,662

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2302861► Subscribe
Russian Federation2004118667► Subscribe
Portugal1448186► Subscribe
MexicoPA04004532► Subscribe
South Korea100956369► Subscribe
South Korea20050044344► Subscribe
Japan4495459► Subscribe
Japan2005514358► Subscribe
Israel161625► Subscribe
Hong Kong1131048► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Chubb
Cerilliant
McKinsey
UBS
Covington
Fish and Richardson
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot